A hemorrhage of off-label use

Annals of Internal Medicine

Volumn 155, Issue 5, 2011, Pages 339-

  Karkouti, Keyvan ^a   Levy, Jerrold H ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROCOAGULANT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; HEMOSTATIC AGENT;

BLEEDING; HUMAN; LETTER; OFF LABEL DRUG USE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; THROMBOSIS; UNSPECIFIED SIDE EFFECT; BLEEDING TENDENCY; BLEEDING TIME; DEATH; HEART INFARCTION; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW (TOPIC); HOSPITAL; NOTE;

FACTOR VIIA; HEMORRHAGE; HEMOSTATICS; HOSPITALS; HUMANS; OFF-LABEL USE;

EID: 80052444140     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-155-5-201109060-00023     Document Type: Letter

References (5)

1. Avorn J, Kesselheim A. A hemorrhage of off-label use [Editorial]. Ann Intern Med. 2011;154:566-567. [PMID: 21502655]
2. Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med. 2011;154:516-522. [PMID: 21502649]
3. Karkouti K, Beattie WS, Arellano R, Aye T, Bussieres JS, Callum JL, et al. Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. Circulation. 2008;118:331-338. [PMID: 18606914]
4. Gill R, Herbertson M, Vuylsteke A, Olsen PS, von Heymann C, Mythen M, et al. Safety and efficacy of recombinant activated factor VII: a randomized placebocontrolled trial in the setting of bleeding after cardiac surgery. Circulation. 2009;120: 21-27. [PMID: 19546387]
5. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363:1791-1800. [PMID: 21047223]